{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:28:26Z","timestamp":1793662106271,"version":"4.5.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.diagmicrobio.2024.116663","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:35:07Z","timestamp":1735346107000},"page":"116663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9712-5718","authenticated-orcid":false,"given":"Eva","family":"Terschl\u00fcsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Aono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-6320","authenticated-orcid":false,"given":"Alisa W.","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mitarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-2003","authenticated-orcid":false,"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082541","article-title":"General overview of nontuberculous mycobacteria opportunistic pathogens: Mycobacterium avium and Mycobacterium abscessus","volume":"9","author":"To","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007083","article-title":"The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases","volume":"13","author":"Baldwin","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0003","article-title":"Real-world treatment patterns in patients with nontuberculous mycobacterial lung disease in general and pneumologist practices in Germany","volume":"20","author":"Diel","year":"2020","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0004","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.rmed.2011.08.004","article-title":"Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease","volume":"105","author":"Mehta","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0005","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12879-018-3113-x","article-title":"High mortality in patients with Mycobacterium avium complex lung disease: a systematic review","volume":"18","author":"Diel","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0006","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of non-tuberculosis mycobacterial lung disease","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0007","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/17476348.2021.1987891","article-title":"Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments","volume":"15","author":"van Ingen","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.rmed.2018.10.022","article-title":"Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population","volume":"145","author":"Marras","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0009","doi-asserted-by":"crossref","first-page":"1900250","DOI":"10.1183\/13993003.00250-2019","article-title":"Non-tuberculous mycobacterial pulmonary disease","volume":"54","author":"Cowman","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0027-2016","article-title":"Rapidly growing mycobacteria","volume":"5","author":"Brown-Elliott","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0011","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0012","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1473-3099(21)00586-7","article-title":"Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0013","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2022.115882","article-title":"In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States","volume":"105","author":"Hunkins","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0015","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1038\/s41598-021-91757-4","article-title":"Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan","volume":"11","author":"Kamada","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0016","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1128\/AAC.46.10.3164-3167.2002","article-title":"Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria","volume":"46","author":"Wallace","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0017","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.rmed.2019.10.006","article-title":"Efficacy and safety of tigecycline for Mycobacterium abscessus disease","volume":"158","author":"Kwon","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01947-20","article-title":"In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against Mycobacteroides abscessus clinical isolates In vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0020","doi-asserted-by":"crossref","first-page":"e01135","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0021","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/cid\/ciz309","article-title":"Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline","volume":"69","author":"Rodvold","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0022","series-title":"Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. CLSI standard M24","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0023","series-title":"Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. CLSI standard M24S-2nd edition","year":"2023"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0024","series-title":"Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. CLSI supplement M62","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0025","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0026","series-title":"CLSI standards: guidelines for health care excellence. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes","author":"Woods","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0027","series-title":"CLSI supplement M100","article-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2023"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0028","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jac\/dkaa520","article-title":"In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens","volume":"76","author":"Chew","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0029","series-title":"Minimum inhibitory concentrations (MICs) of tigecycline correlate strongly with those of omadacycline. Presented at ESCMID Global 2024, April 27-30","author":"de Moura","year":"2024"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2024.102482","article-title":"Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease","volume":"146","author":"Rimal","year":"2024","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0031","doi-asserted-by":"crossref","first-page":"e0066522","DOI":"10.1128\/msphere.00665-22","article-title":"Efficacy of omadacycline-containing regimen in a mouse model of pulmonary Mycobacteroides abscessus disease","volume":"8","author":"Rimal","year":"2023","journal-title":"mSphere"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0032","doi-asserted-by":"crossref","first-page":"e95281","DOI":"10.1371\/journal.pone.0095281","article-title":"Schimmer AD. a novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity","volume":"9","author":"Jitkova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102269","article-title":"Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"137","author":"Shankar","year":"2022","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0034","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0035","article-title":"In vitro antimicrobial activities of tigecycline, eravacycline, omadacycline, and sarecycline against rapidly growing mycobacteria","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0036","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jac\/dkac068","article-title":"Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses","volume":"77","author":"Chapagain","year":"2022","journal-title":"J Antim Chemot"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0037","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0038","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijid.2022.06.061","article-title":"Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series","volume":"122","author":"Duah","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0039","doi-asserted-by":"crossref","first-page":"e01703","DOI":"10.1016\/j.idcr.2023.e01703","article-title":"Omadacycline for the treatment of Mycobacterium abscessus infections: ccase series and review of the literature","volume":"31","author":"Siddiqa","year":"2023","journal-title":"IDCases"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0040","doi-asserted-by":"crossref","first-page":"ofaa415","DOI":"10.1093\/ofid\/ofaa415","article-title":"Omadacycline for the treatment of Mycobacterium abscessus disease: a case series","volume":"7","author":"Pearson","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0041","first-page":"172","article-title":"Use of omadacycline as a component of Mycobacterium abscessus eradication in an adolescent with cystic fibrosis","volume":"28","author":"Tucker","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0042","doi-asserted-by":"crossref","first-page":"ofad335","DOI":"10.1093\/ofid\/ofad335","article-title":"Long-term safety and tolerability of omadacycline for the treatment of Mycobacterium abscessus infections","volume":"10","author":"Mingora","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00824-23","article-title":"Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes","volume":"67","author":"El Ghali","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2024.116663_bib0044","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/imj.16071","article-title":"Omadacycline therapy for Mycobacterium abscessus species infections","volume":"53","author":"Ingram","year":"2023","journal-title":"Intern Med J"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889324004875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889324004875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T09:05:19Z","timestamp":1740560719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889324004875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0732889324004875"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116663","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116663"}}